Lupin Boosts U.S. Generics Business with FDA Approval
MUMBAI, India, and NAPLES, Fla., July 28, 2026 Lupin Limited has received U.S. Food and Drug Administration (FDA) approval...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
MUMBAI, India, and NAPLES, Fla., July 28, 2026 Lupin Limited has received U.S. Food and Drug Administration (FDA) approval...
MUMBAI, India & NAPLES, Fla., June 26, 2026 Lupin Limited announced that it has received tentative approval from the...
Mumbai, India & Naples, Florida | April 10, 2026 Lupin Limited has announced the U.S. launch of Dapagliflozin Tablets...
MIRAMAR, Fla., April 9, 2026 DifGen Pharmaceuticals LLC, in collaboration with Apotex Inc., has announced that the U.S. Food...
ELMWOOD PARK, New Jersey, April 9, 2026 Glenmark Pharmaceuticals Limited has received final approval from the U.S. Food and...
MUMBAI, India & NAPLES, Fla., Feb. 4, 2026 — Global pharmaceutical company Lupin Limited announced the U.S. launch of...
